APVO - Aptevo Therapeutics: Profitability Might Be 12 Months Away
Several days ago, Aptevo Therapeutics (APVO) provided a corporate and pipeline update that surprised me (and I don't get surprised easily).
To begin with, the company's hemophilia B drug IXINITY will do about $9M in revenue for Q3'19. This is a very important milestone for the company, and personally, I think it will change the stock's trajectory going forward.
For starters, $9M represents a 22% sequential increase. One reason for this increase according to the company, was the introduction of the recent larger 3,000 IU assay and the great job the sales team